Expression Profiling of Primary and Recurrent Glioblastomas Reveals a Reduced Level of Pentraxin 3 in Recurrent Glioblastomas
- 13 August 2020
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Neuropathology & Experimental Neurology
- Vol. 79 (9) , 975-985
Abstract
Glioblastomas (GBM) are highly infiltrative tumors and despite intensive treatment tumor recurrence is inevitable. The immune microenvironment in recurrent GBM is poorly characterized, but it is potentially influenced by therapeutic interventions with surgery, radiotherapy, and chemotherapy. The aim of this study was to obtain a deeper insight in the immune microenvironment in primary and recurrent GBM. Primary and recurrent glioblastoma samples from 18 patients were identified and expression profiling of 770 myeloid innate immune-related markers was performed. Leukemia inhibitory factor and pentraxin 3 were expressed at lower levels in recurrent tumors. Using in silico data and immunohistochemical staining, this was validated for pentraxin 3. Both high leukemia inhibitory factor and pentraxin 3 expression appeared to be associated with shorter survival in primary and recurrent GBM using in silico data. In primary GBM, gene set analysis also showed higher expression of genes involved in metabolism, extracellular matrix remodeling and complement activation, whereas genes involved in T cell activation and checkpoint signaling were expressed at higher levels in recurrent GBM. The reduced level of pentraxin 3 in recurrent glioblastomas and the gene set analysis results suggest an altered microenvironment in recurrent GBM that might be more active.Keywords
Funding Information
- Danish Medical Research Council (4183-00183)
This publication has 55 references indexed in Scilit:
- The long pentraxin PTX3 as a correlate of cancer-related inflammation and prognosis of malignancy in gliomasJournal of Neuroimmunology, 2013
- Immunosuppression in Patients with High-Grade Gliomas Treated with Radiation and TemozolomideClinical Cancer Research, 2011
- mRNA transcript quantification in archival samples using multiplexed, color-coded probesBMC Biotechnology, 2011
- Pentraxin-3 Is a Novel Biomarker of Lung CarcinomaClinical Cancer Research, 2011
- Immune modulation effects of concomitant temozolomide and radiation therapy on peripheral blood mononuclear cells in patients with glioblastoma multiformeNeuro-Oncology, 2011
- Anti-VEGF treatment reduces blood supply and increases tumor cell invasion in glioblastomaProceedings of the National Academy of Sciences, 2011
- Hexokinase 2 is a key mediator of aerobic glycolysis and promotes tumor growth in human glioblastoma multiformeJournal of Experimental Medicine, 2011
- Analysis of glial secretome: The long pentraxin PTX3 modulates phagocytic activity of microgliaJournal of Neuroimmunology, 2010
- Commentary on effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5‐Year analysis of the EORTC‐NCIC trial (Lancet Oncol. 2009;10:459‐466)Cancer, 2010
- Radiotherapy plus Concomitant and Adjuvant Temozolomide for GlioblastomaNew England Journal of Medicine, 2005